The drug is indicated for the treatment of alopecia areata - a condition in which the immune system attacks hair follicles, ...

You might associate autoimmune conditions with symptoms like skin disease, chronic pain, and fatigue. A less-discussed ...

Sun Pharma and Incyte Corporation have settled a legal dispute over Leqselvi, a drug used for severe hair loss. Sun has ...

Sun Pharma shares rose nearly 2 per cent on Tuesday after the company launched Leqselvi, a new treatment for severe alopecia ...

Sun Pharmaceutical Industries Limited announced Leqselvi (deuruxolitinib) 8 mg tablets is now available to healthcare providers and people living with severe alopecia areata in the US. Leqselvi is ...

Leqselvi (deuruxolitinib) 8 mg tablets are approved for adults with severe alopecia areata, a disease that causes the immune system to attack hair follicles, leading to partial or complete hair loss ...

LEQSELVI has been approved by the US FDA, following strong results from clinical trials and is now available to adults ...

The delay in Sun Pharma's launch of Leqselvi in the US was caused by a patent infringement case, which was later settled in a ...

"The launch of LEQSELVI in the U.S. brings an effective, new treatment option for severe alopecia areata to eligible patients and the healthcare providers who treat them," said Richard Ascroft, CEO, ...

In a joint statement, the companies announced that both parties will withdraw the ongoing lawsuit and release each other from ...

Over a mean follow-up of 566 days, all-cause mortality rates significantly favored those with ASDs compared with non-ASD ...

Mumbai: Sun Pharmaceutical Industries Limited has announced the launch of LEQSELVI (deuruxolitinib) 8 mg tablets in the U.S.